Targeting colorectal cancer with anti-epidermal growth factor receptor antibodies: focus on panitumumab

References

• ACS cancer facts & figures, www.cancer.org/docroot/stt/stt0.asp, 2008.
   Google Scholar
• MeyerhardtJAMayerRJSystemic therapy for colorectal cancerN Engl J Med200535247648715689586
   PubMed Web of Science ®Google Scholar
• KellyHGoldbergRMSystemic therapy for metastatic colorectal cancer: current options, current evidenceJ Clin Oncol2005234553456016002847
   PubMed Web of Science ®Google Scholar
• HurwitzHFehrenbacherLNovotnyWBevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancerN Engl J Med20043502335234215175435
   PubMed Web of Science ®Google Scholar
• PorebskaIHarlozinskaABojarowskiTExpression of the tyrosine kinase activity growth factor receptors (EGFR, ERB B2, ERB B3) in colorectal adenocarcinomas and adenomasTumour Biol20002110511510686540
   PubMed Web of Science ®Google Scholar
• SpanoJPLagorceCAtlanDImpact of EGFR expression on colorectal cancer patient prognosis and survivalAnn Oncol20051610210815598946
   PubMed Web of Science ®Google Scholar
• CarpenterGCohenSEpidermal growth factorJ Biol Chem1990265770977122186024
   PubMed Web of Science ®Google Scholar
• HemmingAWDavisNLKluftingerAPrognostic markers of colorectal cancer: an evaluation of DNA content, epidermal growth factor receptor, and Ki-67J Surg Oncol1992511471521434639
   PubMed Web of Science ®Google Scholar
• MayerATakimotoMFritzEThe prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancerCancer199371245424608095852
   PubMed Web of Science ®Google Scholar
• CunninghamDHumbletYSienaSCetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancerN Engl J Med200435133734515269313
   PubMed Web of Science ®Google Scholar
• CohenSJCohenRBMeropolNJTargeting signal transduction pathways in colorectal cancer – more than skin deepJ Clin Oncol2005235374538515998904
   PubMed Web of Science ®Google Scholar
• MendelsohnJBaselgaJThe EGF receptor family as targets for cancer therapyOncogene2000196550656511426640
   PubMed Web of Science ®Google Scholar
• VallbohmerDLenzHJEpidermal growth factor receptor as a target for chemotherapyClin Colorectal Cancer20055Suppl 1S19S2715871762
   PubMedGoogle Scholar
• MendelsohnJBaselgaJEpidermal growth factor receptor targeting in cancerSemin Oncol20063336938516890793
   PubMed Web of Science ®Google Scholar
• AaronsonSAGrowth factors and cancerScience1991254114611531659742
   PubMed Web of Science ®Google Scholar
• CiardielloFTortoraGA novel approach in the treatment of cancer: targeting the epidermal growth factor receptorClin Cancer Res200172958297011595683
   PubMed Web of Science ®Google Scholar
• SakoYMinoghchiSYanagidaTSingle-molecule imaging of EGFR signalling on the surface of living cellsNat Cell Biol2000216817210707088
   PubMed Web of Science ®Google Scholar
• MarshallJClinical implications of the mechanism of epidermal growth factor receptor inhibitorsCancer20061071207121816909423
   PubMed Web of Science ®Google Scholar
• FearonERVogelsteinBA genetic model for colorectal tumorigenesisCell1990617597672188735
   PubMed Web of Science ®Google Scholar
• SpanoJPFagardRSoriaJCEpidermal growth factor receptor signaling in colorectal cancer: preclinical data and therapeutic perspectivesAnn Oncol20051618919415668269
   PubMed Web of Science ®Google Scholar
• YangXDJiaXCCorvalanJRDevelopment of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapyCrit Rev Oncol Hematol200138172311255078
   PubMed Web of Science ®Google Scholar
• LynchDHYangXDTherapeutic potential of ABX-EGF: a fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatmentSemin Oncol200229475011894013
   PubMed Web of Science ®Google Scholar
• YangXDJiaXCCorvalanJREradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapyCancer Res1999591236124310096554
   PubMed Web of Science ®Google Scholar
• FoonKAYangXDWeinerLMPreclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibodyInt J Radiat Oncol Biol Phys20045898499014967460
   PubMed Web of Science ®Google Scholar
• FiglinRABX-EGF, a fully human anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) in patients with advanced cancer: phase 1 clinical resultsProc Am Soc Clin Oncol200221abstr 35.
   Google Scholar
• WeinerLMBelldegrunASCrawfordJDose and schedule study of panitumumab monotherapy in patients with advanced solid malignanciesClin Cancer Res20081450250818223225
   PubMed Web of Science ®Google Scholar
• RowinskyEKSchwartzGHGollobJASafety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancerJ Clin Oncol2004223003301515210739
   PubMed Web of Science ®Google Scholar
• MalikIHechtJRPatnaikAVenookASafety and efficacy of panitumumab monotherapy in patients with metastatic colorectal cancer (mCRC)J Clin Oncol2005 ASCO Annual Meeting Proceedings20052316S, Pt I of II June 1 Suppl3520
   Google Scholar
• BerlinJ NMSwansonPHarkerWGBurrisHHechtJRNavaleLPanitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing >10% epidermal growth factor receptor (EGFr)J Clin Oncol2006 ASCO Annual Meeting Proceedings200624 Pt I, No. 18S June 20 Suppl354816877720
   PubMedGoogle Scholar
• HechtJRMitchellEPBarandaJMalikIPanitumumab activity in metastatic colorectal cancer (mCRC) patients (pts) with low or negative tumor epidermal growth factor receptor (EGFr) levels: An updated analysis [abstract]Gastrointestinal Cancers SymposiumOrlando2007119–21 abstract #350.
   Google Scholar
• BerlinJMalikIPicusJPanitumumab therapy with irinotecan, 5-fluorouracil, and leucovorin (IFL) in metastatic colorectal patients [abstract]Proceedings European Society of Medical Oncology2004abstr 265PD.
   Google Scholar
• HechtJPicusJTchekmedyianSHuEPanitumumab in combination with 5-fluorouracil, leucovorin, and irinotecan (IFL) or FOLFIRI for first-line treatment of metastatic colorectal cancer (mCRC) [abstract]Program of the American Society of Clinical Oncology Gastrointestinal Cancers SymposiumSan Francisco2006Abstr 237.
   Google Scholar
• Van CutsemEPeetersMSienaSOpen-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancerJ Clin Oncol2007251658166417470858
   PubMed Web of Science ®Google Scholar
• HechtJRMitchellEChidiacTA randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancerJ Clin Oncol20092767268019114685
   PubMed Web of Science ®Google Scholar
• Amgen: Amgen discontinues Vectibix (TM) treatment in PACCE trial evaluating Vectibix(TM) as part of triple combination regimenAvailable at http://wwwext.amgen.com/media/media_pr_detail.jsp?year=2007&releaseID=977186 Press release 03/22/2007.
   Google Scholar
• PeetersMVan CutsemEHechtJREfficacy and safety of panitumumab across five clinical studies in patients (pts) with metastatic colorectal cancer (mCRC) [abstract #336]Gastrointestinal Cancers SymposiumOrlando2007January 19–21.
   Google Scholar
• PeetersMVan CutsemEBerlinJSafety of panitumumab, a fully human monoclonal antibody against the epidermal growth factor receptor (EGFr), in patients (pts) with metastatic colorectal cancer (mCRC) across clinical trialsJ Clin Oncol2007ASCO Annual Meeting Proceedings Part I(25, No. 18S (June 20 Suppl), 20074138
   Google Scholar
• PeetersMSienaSVan CutsemEAssociation of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapyCancer20091151544155419189371
   PubMed Web of Science ®Google Scholar
• HumbletYPeetersMSienaSAssociation of skin toxicity (ST) severity with clinical outcomes and health-related quality of life (HRQoL) with panitumumab (Pmab) [Abstract #4038]J Clin Oncol200725a18s
   Web of Science ®Google Scholar
• LenzHJVan CutsemEKhambata-FordSMulticenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidinesJ Clin Oncol2006244914492117050875
   PubMed Web of Science ®Google Scholar
• Van CutsemEPeetersMSienaSHumbletYA phase III randomized controlled trial of panitumumab (Pmab) in patients (pts) with metastatic colorectal cancer (mCRC): Subset analyses in elderly pts and in pts with poor performance status [abstract]Gastrointestinal Cancers SymposiumOrlando2007January 19–21. abstract #349.
   Google Scholar
• SaltzLBMeropolNJLoehrerPJSrPhase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptorJ Clin Oncol2004221201120814993230
   PubMed Web of Science ®Google Scholar
• SaltzLEpidermal growth factor receptor-negative colorectal cancer: is there truly such an entity?Clin Colorectal Cancer20055Suppl 2S98S10016336755
   PubMedGoogle Scholar
• ChungKYShiaJKemenyNECetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistryJ Clin Oncol2005231803181015677699
   PubMed Web of Science ®Google Scholar
• HebbarMWacrenierADesauwCLack of usefulness of epidermal growth factor receptor expression determination for cetuximab therapy in patients with colorectal cancerAnticancer Drugs20061785585716926635
   PubMed Web of Science ®Google Scholar
• BosJLRas oncogenes in human cancer: a reviewCancer Res198949468246892547513
   PubMed Web of Science ®Google Scholar
• BosJLFearonERHamiltonSRPrevalence of ras gene mutations in human colorectal cancersNature19873272932973587348
   PubMed Web of Science ®Google Scholar
• BenvenutiSSartore-BianchiADi NicolantonioFOncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapiesCancer Res2007672643264817363584
   PubMed Web of Science ®Google Scholar
• Di FioreFBlanchardFCharbonnierFClinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapyBr J Cancer2007961166116917375050
   PubMed Web of Science ®Google Scholar
• InceWLJubbAMHoldenSNAssociation of k-ras, b-raf, and p53 status with the treatment effect of bevacizumabJ Natl Cancer Inst20059798198915998951
   PubMed Web of Science ®Google Scholar
• EstellerMGonzalezSRisquesRAK-ras and p16 aberrations confer poor prognosis in human colorectal cancerJ Clin Oncol20011929930411208819
   PubMed Web of Science ®Google Scholar
• AndreyevHJNormanARCunninghamDKirsten ras mutations in patients with colorectal cancer: the multicenter “RASCAL” studyJ Natl Cancer Inst1998906756849586664
   PubMed Web of Science ®Google Scholar
• AndreyevHJNormanARCunninghamDKirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ studyBr J Cancer20018569269611531254
   PubMed Web of Science ®Google Scholar
• BazanVMigliavaccaMZannaISpecific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotypeAnn Oncol2002131438144612196370
   PubMed Web of Science ®Google Scholar
• LievreABachetJBLe CorreDKRAS mutation status is predictive of response to cetuximab therapy in colorectal cancerCancer Res2006663992399516618717
   PubMed Web of Science ®Google Scholar
• LievreABachetJBBoigeVKRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximabJ Clin Oncol20082637437918202412
   PubMed Web of Science ®Google Scholar
• De RoockWPiessevauxHDe SchutterJKRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximabAnn Oncol20081950851517998284
   PubMed Web of Science ®Google Scholar
• PaoWMillerVAPolitiKAAcquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domainPLoS Med20052e7315737014
   PubMed Web of Science ®Google Scholar
• FrattiniMSalettiPRomagnaniEPTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patientsBr J Cancer2007971139114517940504
   PubMed Web of Science ®Google Scholar
• AmadoRGWolfMPeetersMWild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancerJ Clin Oncol2008261626163418316791
   PubMed Web of Science ®Google Scholar
• KarapetisCSKhambata-FordSJonkerDJK-ras mutations and benefit from cetuximab in advanced colorectal cancerN Engl J Med20083591757176518946061
   PubMed Web of Science ®Google Scholar
• SantiniDLoupakisFVincenziBHigh concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practiceOncologist2008131270127519056857
   PubMed Web of Science ®Google Scholar
• Di NicolantonioFMartiniMMolinariFWild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancerJ Clin Oncol2008265705571219001320
   PubMed Web of Science ®Google Scholar
• LoupakisFVasileESantiniDEGF-receptor targeting with monoclonal antibodies in colorectal carcinomas: rationale for a pharmacogenomic approachPharmacogenomics20089556918154448
   PubMed Web of Science ®Google Scholar
• LockerGYHamiltonSHarrisJASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancerJ Clin Oncol2006245313532717060676
   PubMed Web of Science ®Google Scholar
• Di CristofanoAPandolfiPPThe multiple roles of PTEN in tumor suppressionCell200010038739010693755
   PubMed Web of Science ®Google Scholar
• AllegraCJJessupJMSomerfieldMRAmerican Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapyJ Clin Oncol2009272091209619188670
   PubMed Web of Science ®Google Scholar